Compare Oracle Corporation (ORCL) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oracle Corporation vs Revvity Inc — how do they compare? Oracle Corporation trades at $162.65 (market cap $468.13B), while Revvity Inc trades at $124.14 (market cap $14.18B). The key difference: Oracle Corporation is far larger — about 33× Revvity Inc's market cap, and Oracle Corporation pays the higher dividend (1.23%). Which is the better fit depends on your goals.
| ORCL | RVTY | |
|---|---|---|
Market Cap | $468.13B | $14.18B |
Sector | Technology | Technology |
52-Week High | $328.33 | $130.94 |
52-Week Low | $114.99 | $82.26 |
Enterprise Value | $597.38B | $16.50B |
Dividend Yield | 1.23% | 0.22% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Oracle (ORCL) trades at $161.70, up 1.81% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $57.40B in 2025, with net income margin expanding to 25.37%. The stock is supported by positive AI infrastructure developments and a consensus analyst price target of $243.38, indicating significant upside potential from current levels.
The outlook remains positive driven by AI partnerships and cloud growth, but risks include high valuation multiples and rising capital expenditures. Institutional sentiment is bullish with 65% buy ratings, though legal scrutiny and competitive pressures warrant monitoring for sustained momentum.
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
